Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
1 study found for:    19487299 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Recruiting Phase II Study of the Optimal Scheme of Administration of Pazopanib in Thyroid Carcinoma
Condition: Thyroid Carcinoma
Interventions: Drug: Continuous pazopanib (Arm A);   Drug: Intermittent pazopanib (Arm B)

Indicates status has not been verified in more than two years